Clinical Trial

A Study of JAB-21822 in Adult Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation in China

Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
To assess safety, tolerability, PK, efficacy and determine recommended phase 2 dose (RP2D) of JAB-21822 (glecirasib) administered in adult participants with KRAS p.G12C-mutant advanced solid tumors.
Protocol Amendment History 1 change
notable Primary completion pushed: 2026-05 -> 2026-08 2026-08-14
Trial Details
NCT Number NCT05009329
Lead Sponsor Allist Pharmaceuticals, Inc.
Conditions NSCLC, Solid Tumor
Enrollment 315 participants
Start Date 2021-07-26
Primary Completion 2026-08 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-08-13